Using EGCG to improve dental treatment for irreversible pulpitis
The Influence of Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy Using Two Different Calcium Silicate-based Materials on Postoperative Pain and Success Rate in Mature Permanent Molars With Irreversible Pulpitis: A Randomized Clinical Trial
This study is testing whether a natural compound called EGCG can work better than a common cleaning solution during dental treatment for patients with irreversible pulpitis to see if it reduces pain and improves healing.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 20 Years to 40 Years |
| Sex | All |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT05811403 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of epigallocatechin gallate (EGCG) compared to sodium hypochlorite as flushing agents during full pulpotomy in mature permanent molars affected by irreversible pulpitis. Participants will be divided into four groups based on the flushing agent and the type of calcium silicate-based material used for pulp capping. The study aims to assess postoperative pain, success rates, and the thickness of the dentin bridge formed after treatment. The findings could provide insights into optimizing dental procedures for better patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are healthy adults aged 20-40 with mature mandibular molars diagnosed with symptomatic irreversible pulpitis.
Not a fit: Patients with non-restorable teeth, signs of pulpal necrosis, or poor periodontal support may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved pain management and treatment success rates for patients undergoing pulpotomy for irreversible pulpitis.
How similar studies have performed: While the use of EGCG in dental treatments is relatively novel, similar studies have shown promising results with other flushing agents in endodontic procedures.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients of either gender between the age group of 20-40 years. 2. Systemically healthy patient (ASA I or II). 3. Mature permanent mandibular molars with: * Extremely deep carious lesion (caries penetrating entire thickness of dentin). * Clinical diagnosis of symptomatic irreversible pulpitis and normal periapical tissue. 4. Patients who agree to provide written consent and attend for recall appointments. Exclusion Criteria: 1. Non-restorable teeth with subgingival caries or badly broken teeth. 2. Signs of pulpal necrosis; associated sinus tract or swelling. 3. Negative response to pulp sensibility test. 4. Poor periodontal support. 5. Absence of pulp exposure following complete caries removal. 6. Bleeding from the pulp could not be detected from one or more of the orifices indicating pulp necrosis. 7. Failure to achieve haemostasis within 10 min following full pulpotomy.
Where this trial is running
Cairo
- Faculty of Dentistry, Cairo University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Anan Medhat
- Email: Anan.Medhat@dentistry.cu.edu.eg
- Phone: 01098708303
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.